Mr Mohammed Asif Chaudry

Surgeon, Consultant Upper GI/Oesophagogastric Surgeon, The Royal Marsden NHS Trust
  • London, GB
  • En, En
  • Best at: Oesophageal and gastric cancer surgery

Mr Mohammed Asif Chaudry qualified from Oxford University with distinction in 1999. His subsequent training in GI and Oesophagogastric Cancer Surgery was at various centres of excellence in London such as St Mark’s Hospital, Barts and The Royal London, University College London and finally The Royal Marsden. His training had a particular focus on a minimally invasive, laparoscopic approach. Upon gaining his CCT he undertook Senior Fellowships at St Thomas’s Hospital with an additional focus on complex open revisional Upper GI surgery. This was followed by international laparoscopic and robotic training at the Seoul National University Hospital in South Korea, the highest volume gastric cancer centre internationally and in Japan. He returned to The Royal Marsden as a Consultant and has a focused high-volume, minimally invasive and open oesophageal and gastric cancer practice dealing with complex cases. He is a founding member of the European Gastric Cancer Association and has an active interest in translational research at the ICR and Biomedical Research Centre. He has publications in high impact factor journals and a number of books published by Oxford University Press.

Send consultation enquiry

Statistics.

Achievements of Mr Mohammed Asif Chaudry

Trustedoctor credentials
-
Clinical endorsements
9
Articles
36
Scientific
co-authors
Trustedoctor credentials
4
General specialty
8
Subspeciality
Languages

About.

Information about Mr Mohammed Asif Chaudry

Timeline
Place
Country
Position
Focus
Since 2015
The Royal College of Surgeons
United Kingdom
Surgeon
Colorectal Surgery
2003-2005
UCL
United Kingdom
Doctorate
Medicine
1993-1999
University of Oxford
United Kingdom
Bachelor of Medicine
Medicine
Timeline
Place
Country
Position
Focus
Since 2013
The Royal Marsden NHS Trust
United Kingdom
The Royal Marsden NHS Foundation Trust Consultant Surgeon, Oesophageal & Gastric Cancer Surgery
Surgery
Since 2016
The Harley Street Clinic
United Kingdom
Consultant Surgeon
Surgery
Since 2015
The Princess Grace Hospital
United Kingdom
Consultant Surgeon
Surgery
Since 1998
NHS England
United Kingdom
Surgeon
Surgery
Timeline
Place
Organization
Position
-
-
-
-
Timeline
Description
Collaboration
-
-
-
Timeline
Place
Award
Position
-
-
-
-

Clinical Experience.

General speciality (1)
Patients per year
Patients total
general gastric cancer surgery
>100
-
Sub-speciality (5)
Patients per year
Patients total
gastrointestinal stromal tumours (gists)
>100
-
mucosa associated lymphoid tissue (malt)
10-50
-
neuroendocrine tumours (nets)
50-100
-
adenocarcinoma
>100
-
carcinoid tumours
10-50
-
Techniques (6)
Patients per year
Patients total
endoscopic resection
50-100
-
total gastrectomy
50-100
-
lymphadenectomy d1
50-100
-
lymphadenectomy d2
50-100
-
gastric bypass (gastrojejunostomy)
50-100
-
endoscopic tumor ablation
50-100
-
General speciality (3)
Patients per year
Patients total
general oesophageal surgery
>100
-
laparoscopic surgery
>100
-
robotic surgery
50-100
-
Sub-speciality (3)
Patients per year
Patients total
adenocarcinoma
>100
-
squamous cell carcinoma
50-100
-
lymphomas
10-50
-
Techniques (5)
Patients per year
Patients total
esophagectomy
>100
-
open esophagectomy
10-50
-
transthoracic esophagectomy
10-50
-
transhiatal esophagectomy
10-50
-
minimally invasive esophagectomy
10-50
-

Skills & Endorsements.

General specialty
general gastric cancer surgery
Sub-speciality
gastrointestinal stromal tumours (gists)
adenocarcinoma
Techniques
robotic surgery
General specialty
general oesophageal surgery
laparoscopic surgery
minimally invasive surgery
robotic surgery

Academic research.

9
Total articles
  • surgery - 4
  • esophageal cancer - 3
  • gastric cancer - 2
  • pancreatic cancer - 1
  • acute kidney injury - 1
  • pulmonary tuberculosis - 1
2
gastrointestinal cancer articles - Impact Factor
  • surgery - 2
Does surgery have a role in managing incurable gastric cancer?

Although the incidence of gastric cancer is decreasing, the outcomes of this disease are among the poorest of all solid-organ tumours, predominantly due to the frequent presence of stage IV metastatic disease at primary presentation. Stage IV gastric cancer is incurable and carries a very poor prognosis (5-year survival rate of ∼4%); palliative chemotherapy remains the standard of care, but increasing evidence indicates that palliative surgery can provide a prognostic and symptomatic benefit, particularly in combination with chemotherapy and/or radiotherapy. Ongoing prospective trials should further clarify the efficacy of palliative surgery in comparison with other treatment modalities. Until such data are available, surgery should not be offered as a standard first-line treatment, but can be considered in selected cases after thorough multidisciplinary discussions involving the patient. Patient selection for both gastrectomy and nonresectional surgery must include consideration of various factors that predict quality of life after surgery. This Perspectives summarizes the available evidence and discusses the utility of palliative surgery in relation to other therapeutic modalities in the management of incurable gastric cancer.

The diagnosis and management of gastric cancer.

Does surgery have a role in managing incurable gastric cancer?

Although the incidence of gastric cancer is decreasing, the outcomes of this disease are among the poorest of all solid-organ tumours, predominantly due to the frequent presence of stage IV metastatic disease at primary presentation. Stage IV gastric cancer is incurable and carries a very poor prognosis (5-year survival rate of ∼4%); palliative chemotherapy remains the standard of care, but increasing evidence indicates that palliative surgery can provide a prognostic and symptomatic benefit, particularly in combination with chemotherapy and/or radiotherapy. Ongoing prospective trials should further clarify the efficacy of palliative surgery in comparison with other treatment modalities. Until such data are available, surgery should not be offered as a standard first-line treatment, but can be considered in selected cases after thorough multidisciplinary discussions involving the patient. Patient selection for both gastrectomy and nonresectional surgery must include consideration of various factors that predict quality of life after surgery. This Perspectives summarizes the available evidence and discusses the utility of palliative surgery in relation to other therapeutic modalities in the management of incurable gastric cancer.

The diagnosis and management of gastric cancer.

Video.

My recent video

Connections.

Map of connections

36
Scientific
co-authors
Our website unfortunately does not support your browser.<br/>Please click <a href="https://www.google.com/chrome/">here</a> to download and install modern browser.
 Supported browsers: Firefox, Chrome, Opera.